Format

Send to

Choose Destination
See comment in PubMed Commons below
J Consult Clin Psychol. 2002 Aug;70(4):887-96.

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.

Author information

  • 1Centers for Behavioral and Preventive Medicine, The Miriam Hospital and Brown Medical School, Providence, Rhode Island 02903, USA. raymond_niaura@brown.edu

Abstract

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

PMID:
12182272
PMCID:
PMC1852538
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Psychological Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk